Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 26.39
QCOR's Cash to Debt is ranked higher than
71% of the 1233 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. QCOR: 26.39 )
QCOR' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: 26.39

Equity to Asset 0.63
QCOR's Equity to Asset is ranked higher than
70% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. QCOR: 0.63 )
QCOR' s 10-Year Equity to Asset Range
Min: -0.11   Max: 0.95
Current: 0.63

-0.11
0.95
F-Score: 5
Z-Score: 14.52
M-Score: -2.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 54.73
QCOR's Operating margin (%) is ranked higher than
98% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -80.68 vs. QCOR: 54.73 )
QCOR' s 10-Year Operating margin (%) Range
Min: -1200   Max: 60.45
Current: 54.73

-1200
60.45
Net-margin (%) 36.05
QCOR's Net-margin (%) is ranked higher than
96% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. QCOR: 36.05 )
QCOR' s 10-Year Net-margin (%) Range
Min: -1033.33   Max: 75.52
Current: 36.05

-1033.33
75.52
ROE (%) 85.24
QCOR's ROE (%) is ranked higher than
99% of the 1124 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. QCOR: 85.24 )
QCOR' s 10-Year ROE (%) Range
Min: -161.22   Max: 104.28
Current: 85.24

-161.22
104.28
ROA (%) 47.94
QCOR's ROA (%) is ranked higher than
99% of the 1231 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. QCOR: 47.94 )
QCOR' s 10-Year ROA (%) Range
Min: -98.06   Max: 74.84
Current: 47.94

-98.06
74.84
ROC (Joel Greenblatt) (%) 1414.97
QCOR's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1204 Companies
in the Global Biotechnology industry.

( Industry Median: -480.34 vs. QCOR: 1414.97 )
QCOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1642.88   Max: 14668.66
Current: 1414.97

-1642.88
14668.66
Revenue Growth (%) 94.00
QCOR's Revenue Growth (%) is ranked higher than
99% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. QCOR: 94.00 )
QCOR' s 10-Year Revenue Growth (%) Range
Min: -12.2   Max: 94.3
Current: 94

-12.2
94.3
EBITDA Growth (%) 106.40
QCOR's EBITDA Growth (%) is ranked higher than
99% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. QCOR: 106.40 )
QCOR' s 10-Year EBITDA Growth (%) Range
Min: -62.2   Max: 117.8
Current: 106.4

-62.2
117.8
EPS Growth (%) 106.60
QCOR's EPS Growth (%) is ranked higher than
99% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. QCOR: 106.60 )
QCOR' s 10-Year EPS Growth (%) Range
Min: -52.5   Max: 106.6
Current: 106.6

-52.5
106.6
» QCOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

QCOR Guru Trades in Q4 2013

John Paulson 731,410 sh (New)
Steven Cohen 520,938 sh (+1525.29%)
Paul Tudor Jones 10,000 sh (+63.93%)
Joel Greenblatt 296,803 sh (+55.43%)
Chuck Royce 48,200 sh (+9.3%)
John Hussman 150,000 sh (unchged)
Paul Tudor Jones 9,500 sh (unchged)
Jim Simons 769,400 sh (-12.04%)
» More
Q1 2014

QCOR Guru Trades in Q1 2014

David Dreman 806 sh (New)
Joel Greenblatt 335,494 sh (+13.04%)
Paul Tudor Jones 35,000 sh (unchged)
John Hussman 150,000 sh (unchged)
John Paulson Sold Out
Paul Tudor Jones 9,200 sh (-8%)
Steven Cohen 416,600 sh (-20.03%)
Chuck Royce 32,200 sh (-33.2%)
Jim Simons 445,400 sh (-42.11%)
» More
Q2 2014

QCOR Guru Trades in Q2 2014

Jeremy Grantham 52,200 sh (New)
Richard Perry 1,164,514 sh (New)
Prem Watsa 6,500 sh (New)
Mario Gabelli 7,100 sh (New)
Louis Moore Bacon 55,000 sh (New)
John Paulson 2,248,913 sh (New)
Paul Tudor Jones 35,000 sh (unchged)
Paul Tudor Jones Sold Out
David Dreman Sold Out
Chuck Royce 31,000 sh (-3.73%)
Joel Greenblatt 319,725 sh (-4.7%)
John Hussman 100,000 sh (-33.33%)
Jim Simons 101,600 sh (-77.19%)
» More
Q3 2014

QCOR Guru Trades in Q3 2014

John Hussman Sold Out
Jeremy Grantham Sold Out
Richard Perry Sold Out
Louis Moore Bacon Sold Out
Mario Gabelli Sold Out
John Paulson Sold Out
Chuck Royce Sold Out
Prem Watsa Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with QCOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Perry 2014-09-30 Sold Out 3%$89.41 - $96.93 $ 93.60%0
John Paulson 2014-09-30 Sold Out 0.9%$89.41 - $96.93 $ 93.60%0
John Hussman 2014-09-30 Sold Out 0.71%$89.41 - $96.93 $ 93.60%0
Joel Greenblatt 2014-09-30 Sold Out 0.37%$89.41 - $96.93 $ 93.60%0
Prem Watsa 2014-09-30 Sold Out 0.04%$89.41 - $96.93 $ 93.60%0
Mario Gabelli 2014-09-30 Sold Out $89.41 - $96.93 $ 93.60%0
Richard Perry 2014-06-30 New Buy3%$67.87 - $93.18 $ 93.69%1164514
John Paulson 2014-06-30 New Buy0.9%$67.87 - $93.18 $ 93.69%2248913
John Hussman 2014-06-30 Reduce -33.33%0.24%$67.87 - $93.18 $ 93.69%100000
Prem Watsa 2014-06-30 New Buy0.04%$67.87 - $93.18 $ 93.69%6500
David Dreman 2014-06-30 Sold Out $67.87 - $93.18 $ 93.69%0
Mario Gabelli 2014-06-30 New Buy$67.87 - $93.18 $ 93.69%7100
John Paulson 2014-03-31 Sold Out 0.2%$50.19 - $79.46 $ 93.647%0
David Dreman 2014-03-31 New Buy$50.19 - $79.46 $ 93.647%806
John Paulson 2013-12-31 New Buy0.2%$51.69 - $69.73 $ 93.658%731410
Joel Greenblatt 2013-12-31 Add 55.43%0.14%$51.69 - $69.73 $ 93.658%296803
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Questcor Pharmaceuticals Inc

Baron Funds Comments on Questcor Pharmaceuticals Inc. - Dec 07, 2012

Shares of Questcor Pharmaceuticals, Inc. (QCOR) were the biggest detractor in the quarter.The company sells a single drug for which it has expanded applications to drive rapid growth. Our research uncovered some red flags which led us to sell out of our position in the quarter. Subsequent to our exit, the stock fell significantly, so I credit our work and instinct for avoiding a bigger loss.

From Baron Funds third quarter letter.


Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 16.40
QCOR's P/E(ttm) is ranked higher than
97% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 16.40 )
QCOR' s 10-Year P/E(ttm) Range
Min: 6.47   Max: 88.1
Current: 16.4

6.47
88.1
P/B 10.12
QCOR's P/B is ranked higher than
64% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 5.68 vs. QCOR: 10.12 )
QCOR' s 10-Year P/B Range
Min: 1.87   Max: 24.88
Current: 10.12

1.87
24.88
P/S 5.91
QCOR's P/S is ranked higher than
88% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 32.77 vs. QCOR: 5.91 )
QCOR' s 10-Year P/S Range
Min: 1.08   Max: 16.53
Current: 5.91

1.08
16.53
PFCF 14.20
QCOR's PFCF is ranked higher than
99% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 14.20 )
QCOR' s 10-Year PFCF Range
Min: 4.86   Max: 52.61
Current: 14.2

4.86
52.61
EV-to-EBIT 9.97
QCOR's EV-to-EBIT is ranked higher than
97% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 9.97 )
QCOR' s 10-Year EV-to-EBIT Range
Min: -559.3   Max: 180.6
Current: 9.97

-559.3
180.6
PEG 0.17
QCOR's PEG is ranked higher than
100% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 0.17 )
QCOR' s 10-Year PEG Range
Min: 0.14   Max: 0.49
Current: 0.17

0.14
0.49
Shiller P/E 41.38
QCOR's Shiller P/E is ranked higher than
97% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 41.38 )
QCOR' s 10-Year Shiller P/E Range
Min: 14.58   Max: 202.33
Current: 41.38

14.58
202.33
Current Ratio 3.17
QCOR's Current Ratio is ranked higher than
65% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. QCOR: 3.17 )
QCOR' s 10-Year Current Ratio Range
Min: 0.92   Max: 34.75
Current: 3.17

0.92
34.75
Quick Ratio 3.08
QCOR's Quick Ratio is ranked higher than
67% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. QCOR: 3.08 )
QCOR' s 10-Year Quick Ratio Range
Min: 0.92   Max: 34.75
Current: 3.08

0.92
34.75

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.28
QCOR's Dividend Yield is ranked higher than
57% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. QCOR: 1.28 )
QCOR' s 10-Year Dividend Yield Range
Min: 0.65   Max: 1.9
Current: 1.28

0.65
1.9
Dividend Payout 0.25
QCOR's Dividend Payout is ranked higher than
97% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 0.25 )
QCOR' s 10-Year Dividend Payout Range
Min: 0.16   Max: 0.39
Current: 0.25

0.16
0.39
Yield on cost (5-Year) 1.28
QCOR's Yield on cost (5-Year) is ranked higher than
54% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.16 vs. QCOR: 1.28 )
QCOR' s 10-Year Yield on cost (5-Year) Range
Min: 0.65   Max: 1.9
Current: 1.28

0.65
1.9
Share Buyback Rate 1.70
QCOR's Share Buyback Rate is ranked higher than
97% of the 835 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. QCOR: 1.70 )
QCOR' s 10-Year Share Buyback Rate Range
Min: 3   Max: -34.5
Current: 1.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 108.84
QCOR's Price/Net Cash is ranked higher than
73% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 105.66 vs. QCOR: 108.84 )
QCOR' s 10-Year Price/Net Cash Range
Min: 6.99   Max: 542.33
Current: 108.84

6.99
542.33
Price/Net Current Asset Value 40.69
QCOR's Price/Net Current Asset Value is ranked higher than
73% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 37.29 vs. QCOR: 40.69 )
QCOR' s 10-Year Price/Net Current Asset Value Range
Min: 4.5   Max: 85
Current: 40.69

4.5
85
Price/Tangible Book 17.30
QCOR's Price/Tangible Book is ranked higher than
66% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. QCOR: 17.30 )
QCOR' s 10-Year Price/Tangible Book Range
Min: 2.63   Max: 81.14
Current: 17.3

2.63
81.14
Price/DCF (Projected) 2.09
QCOR's Price/DCF (Projected) is ranked higher than
96% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 2.09 )
QCOR' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 14.07
Current: 2.09

1
14.07
Price/Median PS Value 1.25
QCOR's Price/Median PS Value is ranked higher than
82% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. QCOR: 1.25 )
QCOR' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 2.66
Current: 1.25

0.26
2.66
Price/Peter Lynch Fair Value 0.66
QCOR's Price/Peter Lynch Fair Value is ranked higher than
100% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 0.66 )
QCOR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.28   Max: 3.1
Current: 0.66

0.28
3.1
Price/Graham Number 3.53
QCOR's Price/Graham Number is ranked higher than
93% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 3.53 )
QCOR' s 10-Year Price/Graham Number Range
Min: 1.2   Max: 17
Current: 3.53

1.2
17
Earnings Yield (Greenblatt) 10.00
QCOR's Earnings Yield (Greenblatt) is ranked higher than
97% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. QCOR: 10.00 )
QCOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 28.7
Current: 10

0.6
28.7
Forward Rate of Return (Yacktman) 93.17
QCOR's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -6.43 vs. QCOR: 93.17 )
QCOR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -73.4   Max: 93.4
Current: 93.17

-73.4
93.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QPH.Germany
Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.
» More Articles for QCOR

Headlines

Articles On GuruFocus.com
John Hussman Purchases 36 New Stocks in Q3 2014 Nov 13 2014 
Prem Watsa Buys 4 New Stocks Aug 13 2014 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
8 Stocks Trying to Be 'Good' by Raising Their Dividends Oct 14 2013 
4 Top-Performing Healthcare Dividend Stocks with Single-Digit P/Es Jul 02 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013 
comment on QCOR Apr 11 2013 
My 3 Favorite High-Yielding Ex-Dividend Stocks for April and 45 Additional to Consider Mar 29 2013 

More From Other Websites
Mallinckrodt shares rise on earnings outlook Oct 14 2014
Mallinckrodt shares rise on earnings outlook Oct 14 2014
Health-Care CIOs Spot Apple Watch Potential Sep 09 2014
The Zacks Analyst Blog Highlights: magicJack VocalTec, RRSat Global Communications Network,... Aug 19 2014
Gulfmark Offshore (GFL) Now Added to S&P SmallCap 600 Index Aug 18 2014
Mallinckrodt Set to Join the S&P 500; Rowan to Join S&P MidCap 400; GulfMark Offshore to Join S&P... Aug 14 2014
QUESTCOR PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Aug 14 2014
Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals Aug 14 2014
Mallinckrodt And Questcor Shareholders Approve Mallinckrodt's Acquisition Of Questcor Aug 14 2014
Prem Watsa Buys 4 New Stocks Aug 13 2014
Salix Q2 Misses Estimates; Novo Nordisk, Mylan Slide Aug 07 2014
Prescription Drugmakers Slide Down Industry Rankings Aug 04 2014
Institutional Shareholder Services Inc. And Glass Lewis Recommend That Shareholders Of Mallinckrodt... Aug 04 2014
QUESTCOR PHARMACEUTICALS INC Financials Jul 31 2014
QUESTCOR PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 30 2014
Greenlight Sees Mallinckrodt Short as Cheap Debt Fuels Deals Jul 25 2014
Einhorn bought Lam Research shares, sold Rite Aid last quarter Jul 25 2014
Greenlight discloses short positions in Safeway, Questcor, Bloomberg says Jul 25 2014
Questcor (QCOR) Misses on Q2 Earnings, Beats on Revenues Jul 25 2014
QUESTCOR PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK